|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A multicenter, randomized,controlled trial comparing Surfaxin (Lacinactant) lavage with standard care for treatment of meconium aspiration syndrome显示文摘 | Wiswell TE Knight GR Finer NN | 2002 | Pediatrics2002，109，6： | 1 |
| 2 | A multicenter randomized controlled trial comparing surfaxin(Lucinactant) lavage with standard care for treatment of meconium aspiration syndrome显示文摘 | Wiswell TE Knight GR Finer NN | 2002 | Pediatrics2002，109，10： | 1 |
| 3 | Biopsychosoeial fac- tors related to depression in aged care residents显示文摘 | Davison TE McCabe MP Knight T | 2012 | J Affect Dis- ord2012，142，123： | 1 |
| 4 | Solar (brachioradial) pruritus--response to capsaicin Cream显示文摘 | Knight TE Hayashi T | 1994 | Int J Dermatol1994，33，3： | 1 |
| 5 | A multicenter, randomized, controlled trial comparing surfaxin (Lucinactant) lavage with standard care for treatment of meconium aspiration syndrome 显示文摘 | Wiswell TE Knight GR Finer NN Donn SM Desai H Walsh WF | 2002 | Pediatrics2002，109，6： | 1 |
| 6 | Direct imaging of trans- venous radiofrequency cardiac ablation using a steerable fiberoptic infrared endoscope显示文摘 | Knight BP Burke MC Hong TE | 2005 | Heart Rhythm2005，2，10： | 1 |
| 7 | A multicenter, randomized, controlled trial comparing surfaxin (lueinactant) lavage with standard care for treatment of meeonium apsiration syndrome 显示文摘 | Wiswell TE Knight GR Finer NN | 2002 | Pediatrics2002，109，6： | 1 |
| 8 | A muhicenter, randomized, controlled trial comparing Surfaxin (Lucinactant) lavage with standard care for treatment of meconium aspiration syndrome显示文摘 | Wiswell TE Knight GR Finer NN | 2002 | Pediatrics2002，109，6： | 1 |
| 9 | Fibrous lesions of the breast:imaging athologic correlation显示文摘 | Goel NB Knight TE Pandey S | 2005 | Radiographics2005，25，6： | 1 |
| 10 | CNB-001 reduces paraplegia in rabbits following spinal cord ischemia显示文摘aortic aneurysm repair and thoracic endovascular aortic repair results in devastating clinical deficits in patients. Because spinal cord ischemia is inadequately treated, we studied the effects of [4-((1E)-2-(5-(4-hydroxy-3-methoxystyryl-)-1-phenyl-1H-pyrazoyl-3-yl) vinyl)-2-methoxy-phenol)](CNB-001), a novel curcumin-based compound, in a rabbit SCI model. CNB-001 is known to inhibit human 5-lipoxygenase and 15-lipoxygenase and reduce the ischemia-induced inflammatory response. Moreover, CNB- 001 can reduce the level of oxidative stress markers and potentiate brain-derived neurotrophic factor and brain-derived neurotrophic factor receptor signaling. The Tarlov scale and quantal analysis technique results revealed that CNB-001 administered as an intravenous dose (bolus) 30 minutes prior to spinal cord ischemia improved the behaviors of female New Zealand White rabbits. The improvements were similar to those produced by the uncompetitive N-methyl-D-aspartate receptor antagonist memantine. At 48 hours after aortic occlusion, there was a 42.7% increase (P < 0.05) in tolerated ischemia duration (n = 14) for rabbits treated with CNB-001 (n = 16), and a 72.3% increase for rabbits treated with the positive control memantine (P < 0.05)(n = 23) compared to vehicle-treated ischemic rabbits (n = 22). CNB-001 is a potential important novel treatment for spinal cord ischemia induced by aortic occlusion. All experiments were approved by the CSMC Institutional Animal Care and Use Committee (IACUC #4311) on November 1, 2012. | Paul A. Lapchak Paul D. Boitano Rene Bombien Daisy Chou Margot Knight Anja Muehle Mihaela Te Winkel Ali Khoynezhad | 2019 | Neural Regeneration Research2019，14，12： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员